DK313688D0 - Anvendelse af doxazosin til fremstilling af farmaceutiske praeparater mod atherosclerose - Google Patents

Anvendelse af doxazosin til fremstilling af farmaceutiske praeparater mod atherosclerose

Info

Publication number
DK313688D0
DK313688D0 DK313688A DK313688A DK313688D0 DK 313688 D0 DK313688 D0 DK 313688D0 DK 313688 A DK313688 A DK 313688A DK 313688 A DK313688 A DK 313688A DK 313688 D0 DK313688 D0 DK 313688D0
Authority
DK
Denmark
Prior art keywords
atherosclerosis
doxazosin
preparation
pharmaceutical preparations
retarding
Prior art date
Application number
DK313688A
Other languages
English (en)
Other versions
DK170499B1 (da
DK313688A (da
Inventor
Archie Calhoun Swindell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of DK313688D0 publication Critical patent/DK313688D0/da
Publication of DK313688A publication Critical patent/DK313688A/da
Application granted granted Critical
Publication of DK170499B1 publication Critical patent/DK170499B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DK313688A 1987-08-26 1988-06-09 Anvendelse af doxazosin til fremstilling af farmaceutiske præparater mod atherosclerose DK170499B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8971687 1987-08-26
US07/089,716 US4758569A (en) 1987-08-26 1987-08-26 Doxazosin as an anti-atherosclerosis agent

Publications (3)

Publication Number Publication Date
DK313688D0 true DK313688D0 (da) 1988-06-09
DK313688A DK313688A (da) 1989-02-27
DK170499B1 DK170499B1 (da) 1995-10-02

Family

ID=22219243

Family Applications (1)

Application Number Title Priority Date Filing Date
DK313688A DK170499B1 (da) 1987-08-26 1988-06-09 Anvendelse af doxazosin til fremstilling af farmaceutiske præparater mod atherosclerose

Country Status (15)

Country Link
US (1) US4758569A (da)
EP (1) EP0305028B1 (da)
JP (1) JPS6471817A (da)
KR (1) KR910002145B1 (da)
AT (1) ATE77552T1 (da)
AU (1) AU594880B2 (da)
CA (1) CA1323572C (da)
DE (1) DE3872333T2 (da)
DK (1) DK170499B1 (da)
HU (1) HU204196B (da)
IE (1) IE60005B1 (da)
IL (1) IL86735A (da)
MY (1) MY103102A (da)
NZ (1) NZ225053A (da)
ZA (1) ZA884237B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
DK0564093T3 (da) * 1992-04-01 2000-03-27 Pfizer Hydroxylerede metabolitter og derivater af doxazosin som antiatherosklerosemidler
US5449679A (en) * 1994-07-29 1995-09-12 Leonard; Robert J. Process and products for reducing biological fluid levels of a lipid soluble waste
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
IL120303A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
MXPA01007952A (es) * 1999-02-05 2004-03-26 Nitrosystems Inc Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
CN1441794A (zh) 2000-07-13 2003-09-10 武田药品工业株式会社 富脂质斑退化剂
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
KR100496436B1 (ko) * 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR100538641B1 (ko) * 2002-07-30 2005-12-22 씨제이 주식회사 암로디핀의 유기산염
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
KR100467669B1 (ko) 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
CN100394989C (zh) 2002-11-15 2008-06-18 华沙整形外科股份有限公司 包含微粒状基于胶原材料的组合物的制药应用和包含所述组合物的滑膜关节
US8118779B2 (en) 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
US8399619B2 (en) 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130647A (en) * 1977-07-08 1978-12-19 Pfizer Inc. Methods for treating congestive heart failure and ischemic heart disease
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4361564A (en) * 1978-11-30 1982-11-30 Edwards K David G Renoprotective treatments employing vasodilator compounds
US4532135A (en) * 1981-02-09 1985-07-30 Edwards K David G Renoprotective treatments employing vasodilator compounds
US4582832A (en) * 1984-10-09 1986-04-15 Pfizer Inc. Trimazosin as an anti-atherosclerosis agent

Also Published As

Publication number Publication date
JPS6471817A (en) 1989-03-16
IL86735A (en) 1994-05-30
DE3872333D1 (de) 1992-07-30
MY103102A (en) 1993-04-30
DK170499B1 (da) 1995-10-02
EP0305028B1 (en) 1992-06-24
KR890003379A (ko) 1989-04-14
IL86735A0 (en) 1988-11-30
ZA884237B (en) 1990-02-28
ATE77552T1 (de) 1992-07-15
EP0305028A2 (en) 1989-03-01
HU204196B (en) 1991-12-30
EP0305028A3 (en) 1990-03-14
KR910002145B1 (ko) 1991-04-06
US4758569A (en) 1988-07-19
AU1752988A (en) 1989-03-02
IE881695L (en) 1989-02-26
DK313688A (da) 1989-02-27
JPH0575729B2 (da) 1993-10-21
NZ225053A (en) 1997-02-24
DE3872333T2 (de) 1992-12-03
IE60005B1 (en) 1994-05-18
CA1323572C (en) 1993-10-26
HUT51141A (en) 1990-04-28
AU594880B2 (en) 1990-03-15

Similar Documents

Publication Publication Date Title
DK313688A (da) Anvendelse af doxazosin til fremstilling af farmaceutiske praeparater mod atherosclerose
NO900077D0 (no) Fremgangsmaate for fremstilling av azitromycin-dihydrat.
FI93350C (fi) Menetelmä uusien farmakologisesti aktiivisten katekolijohdoksien valmistamiseksi
BA98214B1 (bs) Postupak za stabilizaciju nikorandil preparata
IT8722481A0 (it) Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse.
FI97951B (fi) Menetelmä kiinteiden oraalisesti käytettävien ifosfamidivalmisteiden valmistamiseksi
DK536088D0 (da) Lipidregulerende praeparater
ES551866A0 (es) Procedimiento de preparacion de nuevos derivados alquilamino-furanonas y de sales y diastereoisomeros farmaceuticamente aceptables de los mismos.
DK0521967T3 (da) Ny anvendelse af bambuterol
IT8321080A0 (it) Procedimento per la preparazione dell'estere metilico di alfa-l-aspartil-l-fenil-alanina.
FI893478A (fi) Menetelmä uusien kysteiinijohdannaisten valmistamiseksi
NO882655L (no) Fremgangsmaate for fremstilling av (e)-2-(p-fluorfenethyl)-3-fluorallylamin.
NO924763D0 (no) Ny fremgangsmaate for fremstilling av 4-amino-5-hexensyre
ES529565A0 (es) Procedimiento de preparacion de eteres oximas basicos, y de sus sales de adicion acidas farmaceuticamente aceptables
NO162964C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrazolopyridinderivater.
IT1224555B (it) Procedimento per la preparazione di calcestruzzo proiettato
NO881820L (no) Oralt preparat inneholdende antitannstenmidler.
NO894484L (no) Fremgangsmaate for fremstilling av ferrosilisium med lavt titaninnhold.
SE9200741D0 (sv) Blotta (foerfarande foer ny spelform med konventionellt system)
NO880034D0 (no) Fremgangsmaate for fremstilling av krystallinsk aminobeskyttet beta-benzyl-l-aspartinsyre.
IT8721890A0 (it) Composti amminici stericamente impediti e procedimento per la loro preparazione.
DK98389D0 (da) Formuleringer af liposomale antineoplastiske midler med hoeje medikament-lipid-forhold
IT8721769A0 (it) Tioderivati beta-lattamici farmacologicamente attivi eprocedimento per la loro preparazione.
BR1100677A (pt) Formulações lipìdicas de prostaglandinas
LV5716A4 (lv) Farmaceitiski pienemami sali

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired